{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"106.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Cmax is defined as the observed maximum plasma concentration post drug administration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who were enrolled in enriched RP2D cohort received single dose of Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally with food on Day -7.","id":"OG000","title":"RP2D Cohort: Crizotinib 250 mg With Food"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The food effect analysis set included all participants treated (including Day -7 dose) and in the RP2D cohort who had received a dose of crizotinib under fed conditions and for which at least 1 PK parameter of interest (Cmax or AUC) was available. Here, \"Overall number of participants analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"pre-dose, 1, 2, 4, 6, 8, 9, and 24 hours post-dose on Day -7","title":"RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food","type":"PRIMARY","unitOfMeasure":"nanogram per milliliter"}